Personalised therapeutic cancer vaccine shows benefit in Phase III lymphoma trial
This article was originally published in Scrip
Executive Summary
Biovest International's (Accentia Biopharmaceuticals) therapeutic cancer vaccine BiovaxID looks to have become the first to improve disease-free survival (DFS) in follicular lymphoma (FL) in the pivotal Phase III BV-301 study that was highlighted at a plenary session at the ASCO meeting in Orlando.